Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML). Although these combinations are also commonly used in relapsed or refractory AML (RR-AML), clinical and m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Stahl, Maximilian, Menghrajani, Kamal, Derkach, Andriy, Chan, Alexander, Xiao, Wenbin, Glass, Jacob, King, Amber C., Daniyan, Anthony F., Famulare, Christopher, Cuello, Bernadette M., Horvat, Troy Z., Abdel-Wahab, Omar, Levine, Ross L., Viny, Aaron D., Stein, Eytan M., Cai, Sheng F., Roshal, Mikhail, Tallman, Martin S., Goldberg, Aaron D.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2021
Materias:
Myeloid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948282/
https://ncbi.nlm.nih.gov/pubmed/33687434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003734
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares